Presant Cary A, Jacobson Joth, Wolf Walter, Waluch Victor, Weitz Ilene C, Macdonald John S
Los Angeles Oncologic Institute, St. Vincent Medical Center, CA, USA.
Invest New Drugs. 2002 Nov;20(4):369-76. doi: 10.1023/a:1020651311866.
We previously documented that there was an association between the intra-tumoral pharmacokinetics (TPK) of 5-FU and response to therapy with 5-FU and leucovorin (p < .0001). Since we have shown that other modulators of 5-FU, such as methotrexate, interferon and neutrexin alter its TPK, it was of interest to determine if the modulating effect of leucovorin would also alter the tumoral PK of 5-FU. In order to determine the effect of leucovorin on intratumoral 5-FU pharmacokinetics, 23 patients (21 evaluable) underwent 19F magnetic resonance spectroscopy (19F-MRS) twice. The first 19F-MRS was following 5-FU 600 mg/m2 alone, and the second 19F-MRS was following by leucovorin 500 mg/m2 and then 5-FU 600 mg/m2.
A comparison of the intratumoral 5-FU pharmacokinetics indicated that there was no general effect of leucovorin on the intratumoral half-life of 5-FU. In only two of these 21 patients was the half-life of 5-FU altered, and in both cases it was decreased by more than 20%. Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes). There was a statistically significant correlation between tumor response and the intratumoral T1/2 of 5-FU, consistent with our prior results in a larger number of patients. However, there was no statistically significant correlation of time-to-progression or survival with classification of the patients into trappers or non-trappers, probably due to the small sample size in this current study.
The data reported here are compatible with the hypothesis that leucovorin enhancement of 5-fluorouracil antitumor responses is not mediated by the levels of 5-FU in tumors, but rather, is due to the modulation by leucovorin of cellular metabolic processes that follow the uptake of free 5-FU into the tumor cell. The MRS technique may be useful in selected instances for elucidating the possible metabolic interactions of drugs in vivo.
我们之前记录了5-氟尿嘧啶(5-FU)的肿瘤内药代动力学(TPK)与5-FU和亚叶酸联合治疗反应之间存在关联(p <.0001)。由于我们已表明5-FU的其他调节剂,如甲氨蝶呤、干扰素和奈曲毒素会改变其TPK,因此确定亚叶酸的调节作用是否也会改变5-FU的肿瘤药代动力学很有意义。为了确定亚叶酸对肿瘤内5-FU药代动力学的影响,23例患者(21例可评估)接受了两次19F磁共振波谱(19F-MRS)检查。第一次19F-MRS在单独给予600mg/m2的5-FU后进行,第二次19F-MRS在给予500mg/m2的亚叶酸后再给予600mg/m2的5-FU后进行。
肿瘤内5-FU药代动力学的比较表明,亚叶酸对5-FU的肿瘤内半衰期没有普遍影响。在这21例患者中,只有2例5-FU的半衰期发生了改变,且在这两种情况下均降低了20%以上。5-FU加亚叶酸治疗的部分缓解仅见于5-FU肿瘤内半衰期长(滞留)的患者(11例T1/2≥20分钟的患者中有3例部分缓解,相比之下,11例T1/2<20分钟的患者中无部分缓解)。肿瘤反应与5-FU的肿瘤内T1/2之间存在统计学显著相关性,这与我们之前在大量患者中的结果一致。然而,将患者分类为滞留者或非滞留者后,疾病进展时间或生存率与分类之间没有统计学显著相关性,这可能是由于本研究中的样本量较小。
此处报告的数据与以下假设相符,即亚叶酸增强5-氟尿嘧啶抗肿瘤反应不是由肿瘤中5-FU的水平介导的,而是由于亚叶酸对游离5-FU进入肿瘤细胞后细胞代谢过程的调节。MRS技术在某些情况下可能有助于阐明体内药物可能的代谢相互作用。